Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT

Trial Profile

Carfilzomib/Cyclophosphamide/Dexamethasone With Maintenance Carfilzomib in Untreated Transplant-eligible Patients With Symptomatic MM to Evaluate the Benefit of Upfront ASCT

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Apr 2017

At a glance

  • Drugs Carfilzomib (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Acronyms Cardamon
  • Most Recent Events

    • 07 Dec 2015 Planned End Date changed from 1 May 2016 to 1 May 2026 as reported by ClinicalTrails.gov.
    • 07 Dec 2015 Planned primary completion date changed from 1 Jan 2018 to 1 May 2018 as reported by ClinicalTrails.gov.
    • 19 Nov 2015 Accrual to date is 5% according to United Kingdom Clinical Research Network.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top